Hormonal effects of Z-350, possessing steroid 5α-reductase inhibitory and α1-andrenoceptor antagonistic actions, in the rat

Japanese Journal of Pharmacology

Volumn 86, Issue 3, 2001, Pages 323-328

  Fukuda, Y ^a   Fukuta, Y ^a   Higashino, R ^a   Yoshida, K ^a   Ogishima, M ^a   Takei, M ^a   Kurimoto, T ^a  

^a ZERIA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Benign prostatic hyperplasia; Dihydrotestosterone; Steroid 5 reductase; Testosterone; Z 350

Indexed keywords

4 [3 [4 [1 (4 METHYLPHENYL) 3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPOXY]BENZOYL]INDOL 1 YL]BUTYRIC ACID; AGENTS ACTING ON THE GENITAL SYSTEM; ALPHA 1 ADRENERGIC RECEPTOR; ANDROSTANOLONE; ESTRADIOL; FINASTERIDE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; Z 350;

ADRENAL GLAND; ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; EPIDIDYMIS; FEMALE; GROWTH INHIBITION; HORMONAL THERAPY; HORMONE INHIBITION; INHIBITION KINETICS; KIDNEY; LIVER WEIGHT; MALE; NONHUMAN; ORGAN WEIGHT; PROSTATE; PROSTATE HYPERTROPHY; RAT; SEMINAL VESICLE; TESTIS; TISSUE LEVEL; UTERUS WEIGHT;

EID: 0034898534     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.86.323     Document Type: Article

References (33)

1. α-Adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy
2. In vitro characterization of the α-adrenoceptors in human prostate
3. 1-Adrenoceptors in human prostate: Characterization and alteration in benign prostatic hypertrophy
4. Pharmacological characteristic of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue
5. Benign prostatic hyperplasia. Current pharmacological treatment
6. Effects of prazosin on isolated human urethra and in patients with lower moto neuron lesions
7. A randomized placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
8. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction
9. Alfuzosin in the treatment of benign prostatic hyperplasia: Effects of symptoms sores, urinary flow rates and residual volume. A multicenter, double-blind, placebo-controlled trial
10. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy
11. Testosterone, prostate gland and hormone action
12. The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia
13. The clinical development of a 5α-reductase inhibitor, finasteride
14. Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men
15. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers
16. 1-adrenoceptor antagonistic and steroid 5α-reductase inhibitory actions
17. 1-adrenoceptor antagonistic and steroid 5α-reductase inhibitory actions: Pharmacological properties in vivo
18. Analysis of testosterone and dehydroepiandrosterone in saliva by gas chromatography-mass spectrometry
19. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (2) In vivo effects on rat and dog prostates
20. 17β-Acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5α-reductase
21. CGP53153: A new potent inhibitor of 5α-reductase
22. Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat
23. The intranuclear binding of testosterone and 5α-androstan-17β-ol-one by rat prostate
24. Feed-forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase
25. Species differences in prostatic steroid 5α-reductases of rat, dog and human
26. Effects of finasteride on the rat ventral prostate
27. Effects of steroid 5α-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats
28. Effects of a new non-steroidal 5α-reductase inhibitor, FK143, on the prostate gland in beagle dogs
29. The effects of new steroidal anti-androgen, TZP-4238, and chlormadinone acetate on the pituitary and adrenal gland of the rat: Histopathological and immunocytochemical studies
30. Steroidal and nonsteroidal antiandrogens: Chemical structures, mechanisms of action and clinical applications
31. LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats
32. 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign proatatic hyperplasia
33. 1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease